Advancing a rapid onset, targeted and reversible therapy to effectively and safely treat life-threatening clots
About UsOur APPROACH
By developing a targeted, highly specific, short-acting therapy with a direct-acting reversal agent, we aim to make safer, more effective life-saving clot interventions accessible to more patients.
Our work is rooted in a deep understanding of the biology behind clot formation. By targeting von Willebrand Factor (vWF), a key mediator of clot initiation, growth and stabilization, we are advancing a safer and more effective treatment for acute thrombosis.
EXPLORE THE SCIENCE
Our leadership has decades of experience across thrombosis, vascular biology, ischemic disease and drug development and a shared commitment to redefining how thrombosis is treated.
Julia C. Owens, PhD
Chief Executive Officer
Bio
Chief Executive Officer
Dr. Julia C. Owens is Chief Executive Officer of Basking Biosciences, bringing more than 25 years of experience advancing innovative therapies to improve patient outcomes. She is also Chairman of Sena Therapeutics, an advisor to GV (Google Ventures), and a board member of EVOQ Therapeutics and the Biotechnology Innovation Organization (BIO).
Before joining Basking, Dr. Owens founded and led Millendo Therapeutics (NASDAQ: MLND) and served as CEO of Ananke Therapeutics. Earlier in her career, she held business development roles of increasing responsibility at Tularik, QuatRx Pharmaceuticals, and Lycera.
A champion of female leadership in biotech, she co-founded the Biotech CEO Sisterhood. Dr. Owens earned her Ph.D. from the University of California, San Francisco, and bachelor’s degrees in Chemistry and Molecular & Cellular Biology from the University of California, Berkeley.
Richard Shea, MBA
President and Chief Operating Officer
Bio
President and Chief Operating Officer
Mr. Shea joined Basking Biosciences shortly after its founding in 2019. He is an experienced life sciences entrepreneur and has been involved in the creation and growth of multiple life science start-up and growth companies for over the last 20 years. He began his career at Merck. Rich received his MBA from Duke and his B.S. from the University of Notre Dame. Prior to attending Duke, Rich served for 5 years as a Submarine Officer in the U.S. Navy.
Shahid Nimjee, MD, PhD
Co-founder and Chief Medical Officer
Bio
Co-founder and Chief Medical Officer
Shahid Nimjee, M.D., Ph.D., is a Professor and practicing neurosurgeon at The Ohio State University Wexner Medical Center (OSUWMC) where he treats stroke patients. Dr. Nimjee also leads a basic research laboratory at OSUWMC that is focused on evaluating anti-vWF aptamers and their antidotes to treat thromboembolic stroke. At Basking, Dr. Nimjee serves as the Company’s CMO responsible for leading preclinical research activities at his laboratory at OSUWMC and designing the clinical trial plan for BB-031 and BB-025. Shai received his undergrad degree from Yale and his M.D. and Ph.D. degrees from Duke.
Rob Hughes, MBA
Chief Financial Officer
Bio
Chief Financial Officer
Rob is an accomplished financial executive with over 25 years of experience, with considerable experience in building and guiding small, growing life science companies. He brings an in-depth understanding of corporate finance and has expertise in strategic planning, fund raising, financial analysis and reporting, mergers and acquisitions, budgeting and risk management. Prior to Basking, he held leadership roles at Stridebio, Selentity Therapeutics and Viamet Pharmaceuticals. Rob is a CPA and holds a B.S. from the University of Maryland, where he double majored in Finance and Accounting. He also holds an MBA from the University of North Carolina.
Stacy Nelson
Vice President, Global Drug Development
Bio
Vice President, Global Drug Development
Stacy Nelson serves as Vice President, Global Drug Development at Basking Biosciences, where she leads the strategic and operational direction of clinical development programs overseeing study design and execution. With deep experience across clinical operations, regulatory affairs, and business development, Stacy plays a critical role in advancing Basking’s lead program, BB-031, focused on acute ischemic stroke and other thrombotic conditions, as well as the BB-025 program. Prior to joining Basking Biosciences, she has served in senior leadership roles at contract research organizations, biotechnology and pharmaceutical companies, bringing a proven track record of guiding therapies from early-stage research to market. Stacy holds a B.S. from the University of North Carolina at Chapel Hill.
Programs & Pipeline
Our pipeline is focused on developing a therapy that delivers powerful thrombolytic activity in settings of acute thrombosis. BB-031, our lead program, inhibits von Willebrand Factor (vWF) with high specificity, while its direct-acting reversal agent, BB-025, enables the rapid and durable neutralization of BB-031. Together, they represent a new paradigm for safe and effective clot dissolution, offering targeted, potent thrombolysis that can be reversed quickly when needed.
Learn more about our programs
Programs & Pipeline
Our pipeline is focused on developing a therapy that delivers powerful thrombolytic activity in settings of acute thrombosis. BB-031, our lead program, is designed to inhibit von Willebrand Factor (vWF) with high specificity, while its direct-acting reversal agent, BB-025 enables its rapid and durable neutralization. Together, they represent a new paradigm for safe and effective clot dissolution, offering targeted, potent thrombolysis that can be reversed quickly when needed.
Learn more about our programs
